Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, ∼4 years of intensive versus standard glycemic control in participants with type 2 diabetes and other cardiovascular risk factors had a neutral effect on the composite cardiovascular outcome, increased cardiovascular and total mortality, and reduced nonfatal myocardial infarction. Effects of the intervention during prolonged follow-up were analyzed. RESEARCH DESIGN AND METHODS: All surviving ACCORD participants were invited to participate in the ACCORD Follow-on (ACCORDION) study, during which participants were treated according to their health care provider’s judgment. Cardiovascular and other health-related outcomes were prospectively collected and analyzed using an intention-to-treat approach according to the group to which participants were originally allocated. RESULTS: A total of 8,601 people, representing 98% of those who did not suffer a primary outcome or death during the ACCORD trial, were monitored for a median of 8.8 years and a mean of 7.7 years from randomization. Intensive glucose lowering for a mean of 3.7 years had a neutral long-term effect on the primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), death from any cause, and an expanded composite outcome that included all-cause death. Moreover, the risk of cardiovascular mortality noted during the active phase (hazard ratio 1.49; 95% CI 1.19, 1.87; P < 0.0001) decreased (HR 1.20; 95% CI 1.03, 1.39; P = 0.02). CONCLUSIONS: In high-risk people with type 2 diabetes monitored for 9 years, a mean of 3.7 years of intensive glycemic control had a neutral effect on death and nonfatal cardiovascular events but increased cardiovascular-related death.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the epidemiological follow-up of ACCORD in the Action to Control Cardiovascular Risk in Diabetes Follow-On Study (ACCORDION), the excess increase in total mortality that was seen during 3.5 years of intensive treatment was reduced by returning to conventional management, and therefore there was no difference in total mortality after a total of 9 years of follow-up (62).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [62]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“A meta-analysis of the odds ratios for death from ACCORDION and these other three studies using a fixed-effects variance estimate (27) with heterogeneity assessed using the I(2) statistic (28) (Supplementary Table 3) yields an overall mortality odds ratio of 0.”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“A meta-analysis of the odds ratios for death from ACCORDION and these other three studies using a fixed-effects variance estimate (27) with heterogeneity assessed using the I(2) statistic (28) (Supplementary Table 3) yields an overall mortality odds ratio of 0.”
MethodTurner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“9% reduced the 18-year incidence of myocardial infarction by 15% and death by 13% in people with newly diagnosed type 2 diabetes (24).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Cited by
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Basic Mechanisms of Diabetic Heart Disease
Ritchie, R. H., & Abel, E. D. (2020) · Circulation Research · doi:10.1161/circresaha.120.315913 · Cited by 708
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
Gæde, P., Oellgaard, J., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4065-6 · Cited by 528
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s006 · Cited by 486
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s006 · Cited by 440
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Reducing major risk factors for chronic kidney disease
Luyckx, V. A., Tuttle, K. R., Garcia-Garcia, G., Gharbi, M. B., Heerspink, H. J. L., Johnson, D. W., Liu, Z.-H., Massy, Z. A., Moe, O., Nelson, R. G., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.003 · Cited by 254
Intensive glucose control in patients with type 2 diabetes - 15-year follow-up.
Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806802 · Cited by 228
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137186 · Cited by 194
“13 As more diabetes drugs came to the market, there was concern regarding the effect of these drugs on cardiovascular risk, particularly with the drug rosiglitazone, which was associated with a significant increase in the risk of myocardial infarction.”
BackgroundElam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riddle, M. C., Rydén, L., Xavier, D., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13028 · Cited by 183
“Trials of glucometabolic therapies in people with diabetes have shown that intensive glucose-lowering modestly reduces cardiovascular outcomes, mainly because of an effect on ischaemic heart disease, and has an uncertain effect on mortality.(16) Other studies that focused on drug effects rather than glucose-lowering e…”
BackgroundThe Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0024 · Cited by 178
Self-citationPreventing CKD in Developed Countries
Luyckx, V. A., Cherney, D. Z. I., & Bello, A. K. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2019.12.003 · Cited by 176
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Glycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
Insulin Regulation of Proteostasis and Clinical Implications
James, H. A., O'Neill, B. T., & Nair, K. S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.010 · Cited by 121
Buyadaa, O., Magliano, D. J., Salim, A., Koye, D. N., & Shaw, J. E. (2019) · Diabetes Care · doi:10.2337/dc19-1438 · Cited by 118
“The ACCORDION study continued observation of willing participants (n5 8,601) representing 98% of 8,777 people without a primary outcome event for long-term follow-up after they completed the trial (14).”
BackgroundMethodGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Au Yeung, S. L., Luo, S., & Schooling, C. M. (2018) · Diabetes Care · doi:10.2337/dc18-0289 · Cited by 92
“intensive glycemic control did not substantially reduce the risk of cardiovascular disease (CVD) events and may even have increased overall mortality (5), which remained evident after prolonged follow-up (6,7).”
BackgroundKloecker, D. E., Davies, M. J., Khunti, K., & Zaccardi, F. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3286 · Cited by 105
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Tai, S., Fu, L., Zhang, N., Yang, R., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01599-1 · Cited by 95
“[25] and ACCORD Follow-On (ACCORDION) studies [26], we evaluated the association between cumulative TyG index exposure during early follow-up and the incidence of MACEs later in life.”
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
Koška, J., Gerstein, H. C., Beisswenger, P. J., & Reaven, P. D. (2022) · Diabetes Care · doi:10.2337/dc21-2196 · Cited by 89
“5 years following the closeout visit (14), the measurements were repeated at either 24 or 30 months and again at either 54 or 60 months.”
BackgroundCheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Ix, J. H., Pecoits‐Filho, R., Perkovic, V., Sarnak, M. J., Tobe, S. W., Tomson, C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.025 · Cited by 81
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 78
Segar, M. W., Patel, K. V., Vaduganathan, M., Caughey, M. C., Butler, J., Fonarow, G. C., Grodin, J. L., McGuire, D. K., & Pandey, A. (2020) · Diabetes Care · doi:10.2337/dc19-2541 · Cited by 70
“are described in Supplementary Material (9,17,18).”
MethodInfluentialEffect of Intensive Glycemic Control on Risk of Lower Extremity Amputation
Goldman, M. P., Clark, C. J., Craven, T. E., Davis, R. P., Williams, T. K., Velazquez-Ramirez, G., Hurie, J. B., & Edwards, M. S. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.09.021 · Cited by 70
Fiber Optic Sensors: A Review for Glucose Measurement
Cano-Pérez, J. L., Gutiérrez-Gutiérrez, J., Perezcampos-Mayoral, C., Pérez‐Campos, E., Pina-Canseco, M. D. S., Tepech-Carrillo, L., Mayoral, L. P.-C., Vargas-Treviño, M., Apreza, E. L., & Laguna, R. R. (2021) · Biosensors · doi:10.3390/bios11030061 · Cited by 76
Schernthaner, G., Brand, K. M. G., & Bailey, C. J. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155160 · Cited by 77
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 70
Frazier, R., Mehta, R., Cai, X., Lee, J., Napoli, S., Craven, T., Tuazon, J., Safdi, A., Scialla, J., Susztak, K., et al. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2018.09.006 · Cited by 63
Wang, D., Hu, X., Lee, S. H., Chen, F., Jiang, K., Tu, Z., Liu, Z., Du, J., Wang, L., Yin, C., et al. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.005 · Cited by 60
Johnson, J. D. (2016) · Diabetologia · doi:10.1007/s00125-016-4059-4 · Cited by 60
Mancini, G. B. J., O’Meara, E., Zieroth, S., Bernier, M., Cheng, A. Y. Y., Cherney, D. Z. I., Connelly, K. A., Ezekowitz, J., Goldenberg, R. M., Leiter, L. A., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.04.029 · Cited by 56
The role of hyperglycaemia in the development of diabetic cardiomyopathy
Hayek, M. S. E., Ernande, L., Bénitah, J., Gomez, A. M., & Pereira, L. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.08.004 · Cited by 63
“Finally, in a recent observational study, HbA1c 7% was a strong predictor for evidence of cardiovascular benefit”
BackgroundWormgoor, S. G., Dalleck, L. C., Zinn, C., & Harris, N. K. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.12.004 · Cited by 63
Exposure to hypoglycemia and risk of stroke
Smith, L., Chakraborty, D., Bhattacharya, P., Sarmah, D., Koch, S., & Dave, K. R. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13872 · Cited by 60
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Tai, S., Fu, L., Zhang, N., Zhou, Y., Xing, Z., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.858209 · Cited by 51
“We thank all participants and ACCORD/ACCORDION investigators for their tremendous support in the trial.”
MethodInfluentialCeriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Frigé, C., Cosmo, S. D., Bartolo, P. D., Cianni, G. D., Fioretto, P., Giorda, C. B., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100666 · Cited by 63
Lim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Van Tassell, B. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13248 · Cited by 42
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 39
Xing, Z., Pei, J., Huang, J., Peng, X., Chen, P., & Hu, X. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.010512 · Cited by 43
Menini, S., Iacobini, C., Fantauzzi, C. B., & Pugliese, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190711102718 · Cited by 41
Diabetes and stroke: An important complication
Bloomgarden, Z. T., & CHILTON, R. J. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13142 · Cited by 41
Charles, K. N., Li, M., Engin, F., Arruda, A. P., Inouye, K., & Hotamışlıgil, G. S. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.051 · Cited by 32
Webb, D. R., Davies, M. J., Jarvis, J., Seidu, S., & Khunti, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107836 · Cited by 36
Shen, Y. H., Dai, Y., Wang, X. Q., Zhang, R., Lu, L., Ding, F. H., & Shen, W. F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0959-1 · Cited by 39
“In fact, the results of prospective ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial showed no differences in composite outcome of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke between intensive and standard BP control [60, 61].”
BackgroundMonnier, L., Colette, C., Schlienger, J.-L., Bauduceau, B., & Owens, D. R. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.007 · Cited by 30
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Nahmias, A., Stahel, P., Xiao, C., & Lewis, G. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00100 · Cited by 31
“A longer follow up of 9 years did show an increase in cardiovascular-related death, but no change in all-cause death and non-fatal cardiovascular events (54).”
BackgroundJacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34
Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Shen, Y., Shi, L., Nauman, E., Katzmarzyk, P. T., Price‐Haywood, E. G., Bazzano, A. N., Nigam, S., & Hu, G. (2020) · Journal of Stroke · doi:10.5853/jos.2019.01704 · Cited by 28
Xu, B.-T., Wan, S., Wu, Q., Xing, Y.-H., He, Y., Huang, W. G., Long, Y., Zhang, C., Xu, Y., & Jiang, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02646-3 · Cited by 34
“To date, the underlying mechanism of DbCM has not been completely elucidated, the main benefits of intensive glycemic control are non-cardiovascular, and existing therapies are based on the treatment of heart failure [5, 6].”
German, C. A., Laughey, B., Bertoni, A. G., & Yeboah, J. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107499 · Cited by 30
Wormgoor, S. G., Dalleck, L. C., Zinn, C., Borotkanics, R., & Harris, N. K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00475 · Cited by 26
Gómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 27
Huangfu, N., Wang, Y., Cheng, J., Xu, Z., & Wang, S. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5704 · Cited by 29
Glycaemic control in people with diabetes following acute myocardial infarction
Esdaile, H., Hill, N. E., Mayet, J., & Oliver, N. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110644 · Cited by 32
Kuo, C., Chen, Y., Hsu, C., Chang, C. C., Chou, R., Li, S., Kuo, S., Huang, P., Chen, J., & Lin, S. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016179 · Cited by 27
Wright, S. M., Hedin, S., McConnell, M. T., Burke, B. V., Watts, S. A., Leslie, D., Aron, D. C., & POGACH, L. M. (2017) · Clinical Diabetes · doi:10.2337/cd17-0060 · Cited by 24
Targets for blood glucose: What have the trials told us
Valensi, P. E., Prévost, G., Schnell, O., Standl, E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319885456 · Cited by 27
Segar, M. W., Patel, K. V., Vaduganathan, M., Caughey, M. C., Jaeger, B. C., Basit, M. A., Willett, D. L., Butler, J., Sengupta, P. P., Wang, T. J., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05426-2 · Cited by 25
Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes
Buyadaa, O., Salim, A., Morton, J. I., Magliano, D. J., & Shaw, J. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-94099-3 · Cited by 26
“6) UACR (mg/g; median [IQR]) 14 (7, 44) 11 (6, 26) 12 (6, 34) 15 (7, 50) 17 (7, 59) 22 (9, 91)”
Liu, C., Sung, P., Li, Y., Huang, W., Lee, T.-W., Huang, C., Lee, T., Chen, T., & Wei, Y. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003707 · Cited by 27
Harris, S. B., Abrahamson, M. J., Ceriello, A., Charpentier, G., Evans, M., Lehmann, R., Liebl, A., Linjawi, S., Holt, R. I. G., Hosszúfalusi, N., et al. (2020) · Drugs · doi:10.1007/s40265-019-01245-3 · Cited by 22
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide
Senior, P. A., Houlden, R. L., Kim, J., MacKay, D., Nagpal, S., Rabi, D. M., Sherifali, D., & BAJAJ, H. S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.002 · Cited by 23
Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”
Cefalu, W. T., Rosenstock, J., LeRoith, D., Blonde, L., & Riddle, M. C. (2016) · Diabetes Care · doi:10.2337/dc16-0405 · Cited by 21
“(8) report on the longterm follow-up of the ACCORD trial,”
BackgroundBody Mass Index, Sex, and Incident Atrial Fibrillation in Diabetes
Singleton, M. J., German, C. A., Soliman, E. Z., Whalen, S. P., Bhave, P. D., Bertoni, A. G., & Yeboah, J. (2020) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2020.08.008 · Cited by 22
The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes
Pasquel, F. J., Gregg, E. W., & Ali, M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.11.001 · Cited by 21
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 24
Qu, W., Chen, Y., Ma, C., Peng, D., Bai, X., Zhao, J., Liu, S., & Luo, L. (2024) · Coatings · doi:10.3390/coatings14020173 · Cited by 24
Russo, G. T., Nicolucci, A., Lucisano, G., Rossi, M. C., Ceriello, A., Prattichizzo, F., Manicardi, V., Rocca, A., Bartolo, P. D., Cosmo, S. D., et al. (2024) · Diabetes · doi:10.2337/db24-0166 · Cited by 22
Tsujimoto, T., & Kajio, H. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.031 · Cited by 19
The Legacy Effect in the Prevention of Cardiovascular Disease
Esmel, E. V., Naval-Álvarez, J., & Sacanella, E. (2020) · Nutrients · doi:10.3390/nu12113227 · Cited by 20
“Differences observed among these trials may be explained due to the fact that the DCCT and UKPDS studies recruited younger patients with new-onset diabetes without known CVD, in contrast to the characteristics of the patients included in the ADVANCE and ACCORD studies [40,62].”
ResultType 2 diabetes and treatment intensification in primary care in Finland
NISKANEN, L. K., Hahl, J., Haukka, J. K., Leppä, E., Miettinen, T. A., Mushnikov, V., Sipilä, R., Tamminen, N., Vattulainen, P., & Korhonen, P. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1199-7 · Cited by 16
Kloecker, D. E., Khunti, K., Davies, M. J., Pitocco, D., & Zaccardi, F. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.047 · Cited by 17
Chernikov, A. A., Severina, A. S., Shamhalova, M., & Shestakova, M. V. (2016) · Diabetes Mellitus · doi:10.14341/7674 · Cited by 19
Nuyujukian, D. S., Zhou, J. J., Koska, J., & Reaven, P. D. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002931 · Cited by 14
“com/HJH/B697); we used an alternative landmark period approach [2] that captured variability during the ACCORD trial, and reported continuous CV-SBP and CVDBP hazard ratios for risk of the primary CVD outcome during the long-term observational follow-up study (ACCORDION, 2005–2009) [22], to provide evidence that the a…”
MethodChronic Kidney Disease Management in Developing Countries
Badro, D. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-74786-2_27-1 · Cited by 25
Up and down waves of glycemic control and lower-extremity amputation in diabetes
Caruso, P., Scappaticcio, L., Maiorino, M. I., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01325-3 · Cited by 15
Tawfik, Y. M. K., Tassell, B. W. V., Dixon, D. L., Baker, W. L., Fanikos, J. R., & Buckley, L. F. (2023) · Diabetes Care · doi:10.2337/dc22-2040 · Cited by 12
Lehrke, M., Leiter, L. A., Hehnke, U., Thiemann, S., Bhandari, A., Meinicke, T. W., & Johansen, O. E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.015 · Cited by 13
Hata, S., Ushigome, E., Hosomi, Y., Yoshimura, T., Takegami, M., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-022-01136-3 · Cited by 14
Senior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”
Manolis, A. S., Manolis, T. A., & Manolis, A. S. (2018) · Drugs · doi:10.1007/s40265-018-0985-4 · Cited by 12
The past decade in type 2 diabetes and future challenges
HADDAD, J. A., & Haddad, A. N. (2018) · HORMONES · doi:10.1007/s42000-018-0080-y · Cited by 11
Dhaliwal, K. K., Upadhya, B., Soliman, E. Z., Beaty, E., Yeboah, J., Bhave, P. D., Whalen, S. P., & Singleton, M. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.05.009 · Cited by 12
Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
Pothen, L., & Balligand, J. (2021) · Antioxidants · doi:10.3390/antiox10111849 · Cited by 11
Kataoka, Y., Yasuda, S., Asaumi, Y., Honda, S., Noguchi, T., Miyamoto, Y., Sase, K., Iwahashi, N., Kawamura, T., Kosuge, M., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108469 · Cited by 10
Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Lavalle-Cobo, A., Masson, W., Lobo, M., Masson, G., & Molinero, G. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00479-1 · Cited by 9
Madsen, J. M., Kjaer, A. K., Lønborg, J. T., Køber, L., Glinge, C., Jabbari, R., & Engstrøm, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02548-w · Cited by 10
Metadata
- Authors
- The ACCORD Study Group
- Corresponding author
- The ACCORD Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-01-28
- Volume
- 39
- Issue
- 5
- Pages
- 701-708
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4839177
- OpenAlex
- W2589131700
- Cited by
- 193
- References
- 35
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 9 · 2023: 16 · 2022: 13 · 2021: 24 · 2020: 27 · 2019: 25 · 2018: 24 · 2017: 18 · 2016: 18
- FWCI
- 28.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA #Y1-HC-9035, IAA#Y1-HC-1010, HHSN268201100027C)
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
- National Eye Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tight glycemic control, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, nonfatal myocardial infarction, non-fatal stroke, ACCORD trial, long-term follow-up, HbA1c
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Prospective Studies, Risk Factors, Incidence, Proportional Hazards Models, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.